Trials / Completed
CompletedNCT00140348
Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine
A Phase I/II Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine in Patients With Metastatic Hormone-Refractory Prostate Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 80 (planned)
- Sponsor
- Cell Genesys · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate clinical and laboratory safety in patients receiving 4 different doses of GVAX® Prostate Cancer Vaccine in order to determine a maximum tolerated dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Immunotherapy allogeneic GM-CSF secreting cellular vaccine |
Timeline
- Start date
- 2001-12-01
- Completion
- 2005-04-01
- First posted
- 2005-09-01
- Last updated
- 2007-12-24
Locations
12 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00140348. Inclusion in this directory is not an endorsement.